- Home
- NTIP vs KZR Comparison
NTIP vs KZR Comparison
Compare NTIP & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- KZR
- Stock Information
- Founded
- NTIP 1990
- KZR 2015
- Country
- NTIP United States
- KZR United States
- Employees
- NTIP N/A
- KZR N/A
- Industry
- NTIP Multi-Sector Companies
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- KZR Health Care
- Exchange
- NTIP Nasdaq
- KZR Nasdaq
- Market Cap
- NTIP 32.0M
- KZR 29.7M
- IPO Year
- NTIP 1998
- KZR 2018
- Fundamental
- Price
- NTIP $1.43
- KZR $6.19
- Analyst Decision
- NTIP
- KZR Hold
- Analyst Count
- NTIP 0
- KZR 4
- Target Price
- NTIP N/A
- KZR $6.00
- AVG Volume (30 Days)
- NTIP 5.4K
- KZR 53.2K
- Earning Date
- NTIP 11-06-2025
- KZR 11-12-2025
- Dividend Yield
- NTIP 6.94%
- KZR N/A
- EPS Growth
- NTIP N/A
- KZR N/A
- EPS
- NTIP N/A
- KZR N/A
- Revenue
- NTIP $150,000.00
- KZR N/A
- Revenue This Year
- NTIP N/A
- KZR N/A
- Revenue Next Year
- NTIP N/A
- KZR N/A
- P/E Ratio
- NTIP N/A
- KZR N/A
- Revenue Growth
- NTIP N/A
- KZR N/A
- 52 Week Low
- NTIP $1.16
- KZR $3.53
- 52 Week High
- NTIP $1.90
- KZR $7.65
- Technical
- Relative Strength Index (RSI)
- NTIP 48.24
- KZR 68.12
- Support Level
- NTIP $1.42
- KZR $6.11
- Resistance Level
- NTIP $1.48
- KZR $6.29
- Average True Range (ATR)
- NTIP 0.05
- KZR 0.13
- MACD
- NTIP -0.00
- KZR -0.07
- Stochastic Oscillator
- NTIP 50.00
- KZR 65.81
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.